Changes to the Code
H.R. 5269 · Reforming and Enhancing Sustainable Updates to Laboratory Testing Services Act of 2025 · Introduced The text as a member of Congress first filed it. Most bills never get further than this.
RESULTS Act
In committee · step 2 of 5
42 U.S.C. § 1395m–1 Improving policies for clinical diagnostic laboratory tests
50 changes the bill asks for here, 33 carried out
- Not carried out:
by striking requirements.—Subject to subparagraph (B) and inserting(i) In general.— Subject to subparagraph (B) and except as provided for in clause (ii) requirements.—;
The bill turns “requirements.—Subject to subparagraph (B)” into a provision of its own, but in § 1395m–1(a)(1)(A) the text doesn't begin with those words. The law may have changed since the bill was drafted.
Technical detail
“requirements.—Subject to subparagraph (B)” does not open the text of /us/usc/t42/s1395m–1/a/1/A - Not carried out:
by striking
paragraph (2)
and insertingparagraph (2)(A)
;“paragraph (2)” isn't in § 1395m–1(a)(1)(B)(i) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“paragraph (2)” not found in /us/usc/t42/s1395m–1/a/1/B/i - Not carried out:
by inserting
, in accordance with the provisions of this section,
beforereport to the Secretary
;“report to the Secretary” isn't in § 1395m–1(a)(1)(B)(i) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“report to the Secretary” not found in /us/usc/t42/s1395m–1/a/1/B/i - Not carried out:
by striking applicable information (as defined in paragraph (3)) for a data collection period (as defined in paragraph (4)) and inserting(I) for a data collection period (as defined in paragraph (4)) beginning before January 1, 2027, applicable information (as defined in paragraph (3))—;
The bill turns “applicable information (as defined in paragraph (3)) for a data collection period (as defined in paragraph (4))” into a provision of its own, but in § 1395m–1(a)(1)(B)(i) the text doesn't begin with those words. The law may have changed since the bill was drafted.
Technical detail
“applicable information (as defined in paragraph (3)) for a data collection period (as defined in paragraph (4))” does not open the text of /us/usc/t42/s1395m–1/a/1/B/i - Not carried out:
by striking the period at the end and inserting
; and
; andThe bill strikes “.” at the end of § 1395m–1(a)(1)(B)(i), but the text there doesn't end with it. The law may have changed since the bill was drafted.
Technical detail
“.” is not at the end of /us/usc/t42/s1395m–1/a/1/B/i - Carried out:
by adding at the end the following new subclause:
(II) for a data collection period beginning on or after January 1, 2027, for each clinical diagnostic laboratory test for which final payment is made under this part to the laboratory during such period.; and
- Not carried out:
by adding at the end the following new clause;(ii) Collection and submission of data.— (I) In general.— With respect to data collection periods for reporting periods beginning on or after January 1, 2028, and for purposes of this section, in the case of a widely available non-ADLT clinical diagnostic laboratory test (as defined in paragraph (2)(E)), the Secretary shall collect and use applicable information from a qualifying comprehensive claims database (as defined in paragraph (2)(C)) of a qualifying independent claims data entity (as defined in paragraph (2)(D)) with which the Secretary has in effect a contract under subclause (II) for each such test furnished during the respective data collection period and for which final payment is made under this part during the year in which such data collection period occurs. (II) Contract with qualifying independent claims data entity for access to applicable information.— As soon as practicable after the date of enactment of this clause, the Secretary shall identify and enter into a contract with a qualifying independent claims data entity for the purpose of, with respect to widely available non-ADLT clinical diagnostic laboratory tests furnished during a data collection period, such entity reporting to the Secretary applicable information from a qualifying comprehensive claims database of the entity for such tests for which final payment is made under this part during the year in which such data collection period occurs and for which there is applicable information within such database for such period..
We can't read how this instruction is worded yet, so it isn't shown in the text.
Technical detail
no-pattern: adding at the end the following new clause; QCONTENT. - Not carried out:
in clause (i), by striking
2025
and inserting2027
;“2025” isn't in § 1395m–1(a)(1)(B)(i) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“2025” not found in /us/usc/t42/s1395m–1/a/1/B/i - Not carried out:
in clause (ii), by striking
beginning January 1, 2026, and ending March 31, 2026
and insertingbeginning January 1, 2028, and ending March 31, 2028
; and“beginning January 1, 2026, and ending March 31, 2026” isn't in § 1395m–1(a)(1)(B)(ii) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“beginning January 1, 2026, and ending March 31, 2026” not found in /us/usc/t42/s1395m–1/a/1/B/ii - Carried out:
in clause (iii), by striking
three years
and inserting4 years
; - Not carried out:
by striking Definition of applicable laboratory.—In this section, the term applicable laboratory means and inserting Definitions.—In this section:(A) Applicable laboratory.— (i) Reporting periods before 2028.— With respect to reporting periods beginning before January 1, 2028, the term
applicable laboratory
means;We can't read how this instruction is worded yet, so it isn't shown in the text.
Technical detail
no-pattern: striking QTEXT and inserting QTEXT QCONTENT; - Not carried out:
in clause (i), in the second sentence, by striking
paragraph
and insertingclause
; andThe bill points to subparagraph (A) of § 1395m–1(a)(2), which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.
Technical detail
target not found: no subparagraph (A) in /us/usc/t42/s1395m–1/a/2 - Not carried out:
by adding at the end the following new clause:
(ii) Reporting periods beginning during 2028 and subsequent years.— With respect to reporting periods beginning on or after January 1, 2028, the term “applicable laboratory” shall have the meaning given such term in section 414.502 of title 42, Code of Federal Regulations, as in …
The bill points to subparagraph (A) of § 1395m–1(a)(2), which isn't there in the Code as we have it. It may have been renumbered or removed since the bill was drafted.
Technical detail
target not found: no subparagraph (A) in /us/usc/t42/s1395m–1/a/2 - Carried out:
by adding at the end the following new subparagraphs:
(B) Non-widely available non-ADLT clinical diagnostic laboratory test.— The term “non-widely available non-ADLT clinical diagnostic laboratory test” means, with respect to a reporting period, a clinical diagnostic laboratory test that is not an advanced diagnostic laboratory …
- Carried out:
by inserting
final
afterThe
; and - Carried out:
by inserting
or from a qualifying comprehensive claims database pursuant to paragraph (1)(A)(ii)
afterreported by a laboratory under this subsection
; - Carried out:
by inserting
(or, with respect to a widely available non-ADLT clinical diagnostic laboratory test, the qualifying comprehensive claims database of the qualifying independent claims data entity with a contract under paragraph (1)(A)(ii))
afterIn the case where an applicable laboratory
; - Carried out:
by striking
payment rate
each place it appears and insertingfinal payment rate
; - Carried out:
by inserting
(and such different payment rates do not relate to the same claim)
afterfor the same payor for the same test
; and - Carried out:
by inserting
or qualifying independent claims data entity, as applicable,
afterthe applicable laboratory
; - Carried out:
in paragraph (9)(A), by inserting
required to be reported by such laboratory
afterin reporting information
; - Carried out:
by striking
by a laboratory
afterinformation disclosed
; and - Carried out:
by inserting
by a laboratory or the qualifying independent claims data entity with a contract under paragraph (1)(A)(ii)
afterunder this subsection
; and - Not carried out:
by striking Regulations.—Not later than June 30, 2015, and inserting(A) For data collection periods before 2027.— Not later than June 30, 2015, for data collection periods beginning before January 1, 2027, Regulations.—; and
The bill turns “Regulations.—Not later than June 30, 2015,” into a provision of its own, but in § 1395m–1(a)(12) the text doesn't begin with those words. The law may have changed since the bill was drafted.
Technical detail
“Regulations.—Not later than June 30, 2015,” does not open the text of /us/usc/t42/s1395m–1/a/12 - Carried out:
by adding at the end the following new subparagraph:
(B) For data collection periods beginning with 2027.— Not later than December 31, 2026, the Secretary shall establish through notice and comment rulemaking parameters for data collection periods beginning on or after January 1, 2027..
- Carried out:
by inserting
and, in the case of widely available non-ADLT clinical diagnostic laboratory tests, with respect to data collection periods for reporting periods beginning on or after January 1, 2028, for each such test furnished by an applicable laboratory with respect to which there is applicable information made available to the Secretary pursuant to paragraph (1)(A)(ii)) of such subsection
afterunder subsection (a) for a data collection period
; and - Carried out:
by inserting
final
beforepayment rates reported
. - Carried out:
in paragraph (1)(A), by striking
paragraph (3)
and insertingparagraphs (3) and (6)
; and - Carried out:
by adding at the end the following new paragraph:
(6) Default payment for widely available non-ADLT clinical diagnostic laboratory tests for periods for which there is no contract with an independent entity or with respect to which there is no data.— (A) In general.— With respect to data collection periods for reporting periods …
- Carried out:
in paragraph (1)(A), by striking
paragraphs (3) and (6)
and insertingparagraphs (3), (6), and (7)
; and - Carried out:
by adding at the end the following new paragraph:
(7) Payment for non-widely available non-ADLT clinical diagnostic laboratory tests for which there is no applicable information.— (A) In general.— For determining payment under this subsection for a year in the case of a non-widely available non-ADLT clinical diagnostic …
- Carried out:
in subsection (c)(3), by inserting
or subsection (b)(7)
afterunder this subsection
. - Carried out:
Section 1834A(b) of the Social Security Act (42 U.S.C. 1395m–1(b)), as amended by paragraphs (2) and (3)(A), is amended by adding at the end the following new paragraph:
(8) Explanation of payment rates.— In the case of a clinical diagnostic laboratory test for which payment is made under this subsection, the Secretary shall make available to the public an explanation of the payment rate for such test, including any supporting data as may be …
- Carried out:
Section 1834A(b)(4)(A) of the Social Security Act (42 U.S.C. 1395m–1(b)(4)(A)) is amended by striking
until the year following
and insertingthrough the year following
. - Carried out:
in the heading, by inserting
and final payment rate
afterinformation
; - Carried out:
in the heading, by striking
In general
and insertingData collection periods before January 1, 2027
; and - Carried out:
by striking
subparagraph (B)
and insertingsubparagraph (C)
; and - Carried out:
by inserting
beginning before January 1, 2027
afterfor a data collection period
; - Carried out:
by redesignating subparagraph (B) as subparagraph (C);
- Carried out:
by inserting after subparagraph (A) the following new subparagraph:
(B) Subsequent data collection periods.— In this section, subject to subparagraph (C), for a data collection period beginning on or after January 1, 2027, the term “applicable information” means— (i) with respect to a widely available non-ADLT clinical diagnostic laboratory test …
- Carried out:
by inserting after subparagraph (C), the following new subparagraph:
(D) Final payment rate.— In this section, for a data collection period beginning on or after January 1, 2027, the term “final payment rate”— (i) means— (I) with respect to a widely available non-ADLT clinical diagnostic laboratory test furnished during a data collection period, …
- Not carried out:
by striking
January 1, 2019
and insertingJanuary 1, 2027
;“January 1, 2019” isn't in § 1395m–1(a)(4)(B) in the Code as we have it. It was there before, as of Public Law 119-73: the law has changed since the bill was written.
Technical detail
“January 1, 2019” not found in /us/usc/t42/s1395m–1/a/4/B - Not carried out:
by striking
June 30, 2019
and insertingJune 30, 2027
; and“June 30, 2019” isn't in § 1395m–1(a)(4)(B) in the Code as we have it. It was there before, as of Public Law 119-73: the law has changed since the bill was written.
Technical detail
“June 30, 2019” not found in /us/usc/t42/s1395m–1/a/4/B - Carried out:
by adding at the end the following new sentence:
In the case of the reporting period after the reporting period described in paragraph (1)(B)(ii) and each subsequent reporting period with respect to clinical diagnostic laboratory tests that are not advanced diagnostic laboratory tests, the term data collection period means the 6-month period beginning January 1st of the year preceding the year during which such reporting period begins.
. - Carried out:
Section 1834A(a)(8)(C) of the Social Security Act (42 U.S.C. 1395m–1(a)(8)(C)) is amended by striking
A medicaid managed care organization
and insertingWith respect to data collection periods for reporting periods beginning before January 1, 2028, a medicaid managed care organization.
. - Not carried out:
in subparagraph (A), by striking
each of 2017 through 2028
and inserting2017 and each subsequent year
;“each of 2017 through 2028” isn't in § 1395m–1(b)(3)(A) in the Code as we have it. It was there before, as of Public Law 119-73: the law has changed since the bill was written.
Technical detail
“each of 2017 through 2028” not found in /us/usc/t42/s1395m–1/b/3/A - Not carried out:
in clause (ii), by striking
2025
and inserting2028
; and“2025” isn't in § 1395m–1(b)(3)(B)(ii) in the Code as we have it. It was there before, as of Public Law 119-73: the law has changed since the bill was written.
Technical detail
“2025” not found in /us/usc/t42/s1395m–1/b/3/B/ii - Not carried out:
in clause (iii), by striking
for each of 2026 through 2028, 15 percent
and insertingfor 2029 and each subsequent year, 5 percent
; and“for each of 2026 through 2028, 15 percent” isn't in § 1395m–1(b)(3)(B)(iii) in the Code as we have it. The law may have changed since the bill was drafted.
Technical detail
“for each of 2026 through 2028, 15 percent” not found in /us/usc/t42/s1395m–1/b/3/B/iii - Carried out:
in subparagraph (C)(ii), by inserting
laboratory
afteradvanced diagnostic
. - Carried out:
Section 1834A(h)(1) of the Social Security Act (42 U.S.C. 1395m–1(h)(1)) is amended by inserting
before January 1, 2029
before the period at the end.
4 of the 50 changes this bill asks for here name words or provisions the section had before but doesn't now: the law has changed since the bill was written, so they are not marked.
§ 1395m–1(a)Reporting of private sector payment rates for establishment of medicare payment rates(1)–(10)
Start of § 1395m–1 to (a)(1)(A) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (1)(B) | (B) Revised reporting period | (B) Revised reporting period | ||
| In the case of reporting with respect to clinical diagnostic laboratory tests that are not advanced diagnostic laboratory tests, the Secretary shall revise the reporting period under subparagraph (A) such that— | In the case of reporting with respect to clinical diagnostic laboratory tests that are not advanced diagnostic laboratory tests, the Secretary shall revise the reporting period under subparagraph (A) such that— | |||
| (1)(B)(i) | (i) | (i) | ||
| no reporting is required during the period beginning January 1, 2020, and ending April 30, 2026; | no reporting is required during the period beginning January 1, 2020, and ending April 30, 2026; | |||
| (1)(B)(i)(II) | (II) [inserted: ] | |||
| [inserted: for a data collection period beginning on or after January 1, 2027, for each clinical diagnostic laboratory test for which final payment is made under this part to the laboratory during such period.] | ||||
| (1)(B)(ii) | (ii) | (ii) | ||
| reporting is required during the period beginning May 1, 2026, and ending July 31, 2026; and | reporting is required during the period beginning May 1, 2026, and ending July 31, 2026; and | |||
| (1)(B)(iii) | (iii) | (iii) | ||
| reporting is required every | reporting is required every [inserted: 4] years after the period described in clause (ii). | |||
| (2) | (2) Definition of applicable laboratory | (2) Definition of applicable laboratory | ||
| In this section, the term “applicable laboratory” means a laboratory that, with respect to its revenues under this subchapter, a majority of such revenues are from this section, section 1395l(h) of this title, or section 1395w–4 of this title. The Secretary may establish a low volume or low expenditure threshold for excluding a laboratory from the definition of applicable laboratory under this paragraph, as the Secretary determines appropriate. | In this section, the term “applicable laboratory” means a laboratory that, with respect to its revenues under this subchapter, a majority of such revenues are from this section, section 1395l(h) of this title, or section 1395w–4 of this title. The Secretary may establish a low volume or low expenditure threshold for excluding a laboratory from the definition of applicable laboratory under this paragraph, as the Secretary determines appropriate. | |||
| (2)(B) | (B) [inserted: Non-widely available non-ADLT clinical diagnostic laboratory test.—] | |||
| [inserted: The term “non-widely available non-ADLT clinical diagnostic laboratory test” means, with respect to a reporting period, a clinical diagnostic laboratory test that is not an advanced diagnostic laboratory test and that is not described in subparagraph (E).] | ||||
| (2)(C) | (C) [inserted: Qualifying independent claims data entity.—] | |||
| [inserted: The term “qualifying independent claims data entity” means an entity that satisfies each of the following criteria:] | ||||
| (2)(C)(i) | (i) [inserted: ] | |||
| [inserted: The entity is a national nonprofit organization that is not affiliated with any Government agency, insurance issuer, group health plan, provider of services or supplier, or other organization in the health care sector.] | ||||
| (2)(C)(ii) | (ii) [inserted: ] | |||
| [inserted: The entity collects data and maintains a qualifying comprehensive claims database (as defined in subparagraph (D)).] | ||||
| (2)(C)(iii) | (iii) [inserted: ] | |||
| [inserted: The entity is certified by the Secretary to be a qualified entity (as defined in paragraph (2) of section 1874(e)) with respect to having access to data described in paragraph (3) of such section.] | ||||
| (2)(C)(iv) | (iv) [inserted: ] | |||
| [inserted: The entity, with respect to all data included in the qualifying comprehensive claims database of the entity, complies with all applicable Federal and State privacy and security requirements, including HIPAA privacy and security law (as defined in section 3009 of the Public Health Service Act).] | ||||
| (2)(C)(v) | (v) [inserted: ] | |||
| [inserted: The entity applies quality assurance processes to validate all data that is included in the qualifying comprehensive claims database of the entity, including comprehensive statistical testing.] | ||||
| (2)(D) | (D) [inserted: Qualifying comprehensive claims database.—] | |||
| [inserted: The term “qualifying comprehensive claims database” means an independent database of private payor claims data, which—] | ||||
| (2)(D)(i) | (i) [inserted: ] | |||
| [inserted: includes at least 50,000,000,000 claims from more than 50 private payors and claims administrators;] | ||||
| (2)(D)(ii) | (ii) [inserted: ] | |||
| [inserted: is a statistically significant repository of claims data that is representative for all 50 States and the District of Columbia;] | ||||
| (2)(D)(iii) | (iii) [inserted: ] | |||
| [inserted: includes only data that is validated by quality assurance processes, including comprehensive statistical testing;] | ||||
| (2)(D)(iv) | (iv) [inserted: ] | |||
| [inserted: complies with all applicable Federal and State privacy and security requirements, as described in subparagraph (C)(iv);] | ||||
| (2)(D)(v) | (v) [inserted: ] | |||
| [inserted: provides for version control of claims to enable the collation and submission, for purposes of this section, of only claims representative of final payment amounts; and] | ||||
| (2)(D)(vi) | (vi) [inserted: ] | |||
| [inserted: includes claims data with respect to widely available non-ADLT clinical diagnostic laboratory tests.] | ||||
| (2)(E) | (E) [inserted: Widely available non-ADLT clinical diagnostic laboratory test.—] | |||
| [inserted: The term “widely available non-ADLT clinical diagnostic laboratory test” means, with respect to a reporting period, a clinical diagnostic laboratory test that is not an advanced diagnostic laboratory test and for which, during the first 6 months of the year immediately preceding the data collection period for such reporting period, the number of providers of services and suppliers receiving payments under this section (as determined by the Secretary using the national provider identifier of the provider of services or supplier on the claim submitted for payment under this part for such test) exceeds 100.] | ||||
| (3) | (3) Applicable information defined | (3) Applicable information [inserted: and final payment rate ]defined | ||
| (3)(A) | (A) | (A) [inserted: Data] [inserted: collection periods before January 1, 2027] | ||
| In this section, subject to subparagraph ( | In this section, subject to subparagraph ([inserted: C]), the term “applicable information” means, with respect to a laboratory test for a data collection period[inserted: beginning before January 1], [inserted: 2027, ]the following: | |||
| (3)(A)(i) | (i) | (i) | ||
| The payment rate (as determined in accordance with paragraph (5)) that was paid by each private payor for the test during the period. | The payment rate (as determined in accordance with paragraph (5)) that was paid by each private payor for the test during the period. | |||
| (3)(A)(ii) | (ii) | (ii) | ||
| The volume of such tests for each such payor for the period. | The volume of such tests for each such payor for the period. | |||
| (3)(B) | (B) [inserted: Subsequent data collection periods.—] | |||
| [inserted: In this section, subject to subparagraph (C), for a data collection period beginning on or after January 1, 2027, the term “applicable information” means—] | ||||
| (3)(B)(i) | (i) [inserted: ] | |||
| [inserted: with respect to a widely available non-ADLT clinical diagnostic laboratory test furnished during such period—] | ||||
| (3)(B)(i)(I) | (I) [inserted: ] | |||
| [inserted: the final payment rate (as determined in accordance with paragraph (5) and defined in subparagraph (D)) that was paid by each private payor for the test during the year in which such period occurs; and] | ||||
| (3)(B)(i)(II) | (II) [inserted: ] | |||
| [inserted: the volume, for each such payor, of such test for which final payment was made during such year; and] | ||||
| (3)(B)(ii) | (ii) [inserted: ] | |||
| [inserted: with respect to a non-widely available non-ADLT clinical diagnostic laboratory test or an advanced diagnostic laboratory test—] | ||||
| (3)(B)(ii)(I) | (I) [inserted: ] | |||
| [inserted: the final payment rate (as determined in accordance with paragraph (5) and defined in subparagraph (D)) that was paid by each private payor for the test during the data collection period; and] | ||||
| (3)(B)(ii)(II) | (II) [inserted: ] | |||
| [inserted: the volume, for each such payor, of such test for which final payment was made during such period.] | ||||
| (3)(C) | [inserted: (C)] Exception for certain contractual arrangements | |||
| Such term shall not include information with respect to a laboratory test for which payment is made on a capitated basis or other similar payment basis during the data collection period. | Such term shall not include information with respect to a laboratory test for which payment is made on a capitated basis or other similar payment basis during the data collection period. | |||
| (3)(D) | (D) [inserted: Final payment rate.—] | |||
| [inserted: In this section, for a data collection period beginning on or after January 1, 2027, the term “final payment rate”—] | ||||
| (3)(D)(i) | (i) [inserted: ] | |||
| [inserted: means—] | ||||
| (3)(D)(i)(I) | (I) [inserted: ] | |||
| [inserted: with respect to a widely available non-ADLT clinical diagnostic laboratory test furnished during a data collection period, the last payment made for a test during the year in which the data collection period occurs; and] | ||||
| (3)(D)(i)(II) | (II) [inserted: ] | |||
| [inserted: with respect to a non-widely available non-ADLT clinical diagnostic laboratory test or an advanced diagnostic laboratory test paid during a data collection period, the last payment made during the data collection period; and] | ||||
| (3)(D)(ii) | (ii) [inserted: ] | |||
| [inserted: does not include—] | ||||
| (3)(D)(ii)(I) | (I) [inserted: ] | |||
| [inserted: denied payments;] | ||||
| (3)(D)(ii)(II) | (II) [inserted: ] | |||
| [inserted: payments under appeal or under review by the private payor;] | ||||
| (3)(D)(ii)(III) | (III) [inserted: ] | |||
| [inserted: payments made in error; or] | ||||
| (3)(D)(ii)(IV) | (IV) [inserted: ] | |||
| [inserted: payments that are recouped by the private payor.] | ||||
| (4) | (4) Data collection period defined | (4) Data collection period defined | ||
| (4)(A) | (A) In general | (A) In general | ||
| Subject to subparagraph (B), in this section, the term “data collection period” means a period of time, such as a previous 12 month period, specified by the Secretary. | Subject to subparagraph (B), in this section, the term “data collection period” means a period of time, such as a previous 12 month period, specified by the Secretary. | |||
| (4)(B) | (B) Exception | (B) Exception | ||
| In the case of the reporting period described in paragraph (1)(B)(ii) with respect to clinical diagnostic laboratory tests that are not advanced diagnostic laboratory tests, the term “data collection period” means the period beginning January 1, 2025, and ending June 30, 2025. | In the case of the reporting period described in paragraph (1)(B)(ii) with respect to clinical diagnostic laboratory tests that are not advanced diagnostic laboratory tests, the term “data collection period” means the period beginning January 1, 2025, and ending June 30, 2025.[inserted: In the case of the reporting period after the reporting period described in paragraph (1)(B)(ii) and each subsequent reporting period with respect to clinical diagnostic laboratory tests that are not advanced diagnostic laboratory tests, the term data collection period means the 6-month period beginning January 1st of the year preceding the year during which such reporting period begins.] | |||
| (5) | (5) Treatment of discounts | (5) Treatment of discounts | ||
| The payment rate reported by a laboratory under this subsection shall reflect all discounts, rebates, coupons, and other price concessions, including those described in section 1395w–3a(c)(3) of this title. | The [inserted: final ]payment rate reported by a laboratory under this subsection [inserted: or from a qualifying comprehensive claims database pursuant to paragraph (1)(A)(ii) ]shall reflect all discounts, rebates, coupons, and other price concessions, including those described in section 1395w–3a(c)(3) of this title. | |||
| (6) | (6) Ensuring complete reporting | (6) Ensuring complete reporting | ||
| In the case where an applicable laboratory has more than one payment rate for the same payor for the same test or more than one payment rate for different payors for the same test, the applicable laboratory shall report each such payment rate and the volume for the test at each such rate under this subsection. Beginning with January 1, 2019, the Secretary may establish rules to aggregate reporting with respect to the situations described in the preceding sentence. | In the case where an applicable laboratory [inserted: (or, with respect to a widely available non-ADLT clinical diagnostic laboratory test, the qualifying comprehensive claims database of the qualifying independent claims data entity with a contract under paragraph (1)(A)(ii)) ]has more than one [inserted: final ]payment rate for the same payor for the same test [inserted: (and such different payment rates do not relate to the same claim) ]or more than one [inserted: final ]payment rate for different payors for the same test, the applicable laboratory [inserted: or qualifying independent claims data entity, as applicable, ]shall report each such [inserted: final ]payment rate and the volume for the test at each such rate under this subsection. Beginning with January 1, 2019, the Secretary may establish rules to aggregate reporting with respect to the situations described in the preceding sentence. | |||
| (7) | (7) Certification | (7) Certification | ||
| An officer of the laboratory shall certify the accuracy and completeness of the information reported under this subsection. | An officer of the laboratory shall certify the accuracy and completeness of the information reported under this subsection. | |||
| (8) | (8) Private payor defined | (8) Private payor defined | ||
| In this section, the term “private payor” means the following: | In this section, the term “private payor” means the following: | |||
| (8)(A) | (A) | (A) | ||
| A health insurance issuer and a group health plan (as such terms are defined in section 300gg–91 of this title). | A health insurance issuer and a group health plan (as such terms are defined in section 300gg–91 of this title). | |||
| (8)(B) | (B) | (B) | ||
| A Medicare Advantage plan under part C. | A Medicare Advantage plan under part C. | |||
| (8)(C) | (C) | (C) | ||
| [inserted: With] [inserted: respect to data collection periods for reporting periods beginning before January 1, 2028, a ]medicaid managed care organization[inserted: .] (as defined in section 1396b(m) of this title). | ||||
| (9) | (9) Civil money penalty | (9) Civil money penalty | ||
| (9)(A) | (A) In general | (A) In general | ||
| If the Secretary determines that an applicable laboratory has failed to report or made a misrepresentation or omission in reporting information under this subsection with respect to a clinical diagnostic laboratory test, the Secretary may apply a civil money penalty in an amount of up to $10,000 per day for each failure to report or each such misrepresentation or omission. | If the Secretary determines that an applicable laboratory has failed to report or made a misrepresentation or omission in reporting information [inserted: required to be reported by such laboratory ]under this subsection with respect to a clinical diagnostic laboratory test, the Secretary may apply a civil money penalty in an amount of up to $10,000 per day for each failure to report or each such misrepresentation or omission. | |||
| (9)(B) | (B) Application | (B) Application | ||
| The provisions of section 1320a–7a of this title (other than subsections (a) and (b)) shall apply to a civil money penalty under this paragraph in the same manner as they apply to a civil money penalty or proceeding under section 1320a–7a(a) of this title. | The provisions of section 1320a–7a of this title (other than subsections (a) and (b)) shall apply to a civil money penalty under this paragraph in the same manner as they apply to a civil money penalty or proceeding under section 1320a–7a(a) of this title. | |||
| (10) | (10) Confidentiality of information | (10) Confidentiality of information | ||
| Notwithstanding any other provision of law, information disclosed by a laboratory under | Notwithstanding any other provision of law, information disclosed [inserted: under this subsection ]by a laboratory [inserted: or the qualifying independent claims data entity with a contract ]under [inserted: paragraph] [inserted: (1)(A)(ii)] is confidential and shall not be disclosed by the Secretary or a Medicare contractor in a form that discloses the identity of a specific payor or laboratory, or prices charged or payments made to any such laboratory, except— | |||
| (10)(A) | (A) | (A) | ||
| as the Secretary determines to be necessary to carry out this section; | as the Secretary determines to be necessary to carry out this section; | |||
| (10)(B) | (B) | (B) | ||
| to permit the Comptroller General to review the information provided; | to permit the Comptroller General to review the information provided; | |||
§ 1395m–1(a)–(b)
(a)(10)(C)–(D) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (a)(11) | (11) Protection from public disclosure | (11) Protection from public disclosure | ||
| A payor shall not be identified on information reported under this subsection. The name of an applicable laboratory under this subsection shall be exempt from disclosure under section 552(b)(3) of title 5. | A payor shall not be identified on information reported under this subsection. The name of an applicable laboratory under this subsection shall be exempt from disclosure under section 552(b)(3) of title 5. | |||
| (a)(12) | (12) Regulations | (12) Regulations | ||
| Not later than June 30, 2015, the Secretary shall establish through notice and comment rulemaking parameters for data collection under this subsection. | Not later than June 30, 2015, the Secretary shall establish through notice and comment rulemaking parameters for data collection under this subsection. | |||
| (a)(12)(B) | (B) [inserted: For data collection periods beginning with 2027.—] | |||
| [inserted: Not later than December 31, 2026, the Secretary shall establish through notice and comment rulemaking parameters for data collection periods beginning on or after January 1, 2027.] | ||||
| (b) | (b) Payment for clinical diagnostic laboratory tests | (b) Payment for clinical diagnostic laboratory tests | ||
| (b)(1) | (1) Use of private payor rate information to determine medicare payment rates | (1) Use of private payor rate information to determine medicare payment rates | ||
| (b)(1)(A) | (A) In general | (A) In general | ||
| Subject to | Subject to [inserted: paragraphs] (3)[inserted: ,] [inserted: (6), ]and [inserted: (7) and ]subsections (c) and (d), in the case of a clinical diagnostic laboratory test furnished on or after January 1, 2017, the payment amount under this section shall be equal to the weighted median determined for the test under paragraph (2) for the most recent data collection period. | |||
| (b)(1)(B) | (B) Application of payment amounts to hospital laboratories | (B) Application of payment amounts to hospital laboratories | ||
| The payment amounts established under this section shall apply to a clinical diagnostic laboratory test furnished by a hospital laboratory if such test is paid for separately, and not as part of a bundled payment under section 1395l(t) of this title. | The payment amounts established under this section shall apply to a clinical diagnostic laboratory test furnished by a hospital laboratory if such test is paid for separately, and not as part of a bundled payment under section 1395l(t) of this title. | |||
| (b)(2) | (2) Calculation of weighted median | (2) Calculation of weighted median | ||
| For each laboratory test with respect to which information is reported under subsection (a) for a data collection period, the Secretary shall calculate a weighted median for the test for the period, by arraying the distribution of all payment rates reported for the period for each test weighted by volume for each payor and each laboratory. | For each laboratory test with respect to which information is reported under subsection (a) for a data collection period[inserted: and], [inserted: in ]the [inserted: case of widely available non-ADLT clinical diagnostic laboratory tests, with respect to data collection periods for reporting periods beginning on or after January 1, 2028, for each such test furnished by an applicable laboratory with respect to which there is applicable information made available to the ]Secretary [inserted: pursuant to paragraph (1)(A)(ii)) of such subsection, the Secretary ]shall calculate a weighted median for the test for the period, by arraying the distribution of all [inserted: final ]payment rates reported for the period for each test weighted by volume for each payor and each laboratory. | |||
| (b)(3) | (3) Phase-in of reductions from private payor rate implementation | (3) Phase-in of reductions from private payor rate implementation | ||
| (b)(3)(A) | (A) In general | (A) In general | ||
| Payment amounts determined under this subsection for a clinical diagnostic laboratory test for each of 2017 through 2029 shall not result in a reduction in payments for a clinical diagnostic laboratory test for the year of greater than the applicable percent (as defined in subparagraph (B)) of the amount of payment for the test for the preceding year. | Payment amounts determined under this subsection for a clinical diagnostic laboratory test for each of 2017 through 2029 shall not result in a reduction in payments for a clinical diagnostic laboratory test for the year of greater than the applicable percent (as defined in subparagraph (B)) of the amount of payment for the test for the preceding year. | |||
§ 1395m–1(b)–(c)
(b)(3)(B)–(C) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (b)(3)(C)(i) | (i) | (i) | ||
| A new test under subsection (c). | A new test under subsection (c). | |||
| (b)(3)(C)(ii) | (ii) | (ii) | ||
| A new advanced diagnostic test (as defined in subsection (d)(5)) under subsection (d). | A new advanced diagnostic [inserted: laboratory ]test (as defined in subsection (d)(5)) under subsection (d). | |||
| (b)(4) | (4) Application of market rates | (4) Application of market rates | ||
| (b)(4)(A) | (A) In general | (A) In general | ||
| Subject to paragraph (3), once established for a year following a data collection period, the payment amounts under this subsection shall continue to apply | Subject to paragraph (3), once established for a year following a data collection period, the payment amounts under this subsection shall continue to apply [inserted: through] the year following the next data collection period. | |||
| (b)(4)(B) | (B) Other adjustments not applicable | (B) Other adjustments not applicable | ||
| The payment amounts under this section shall not be subject to any adjustment (including any geographic adjustment, budget neutrality adjustment, annual update, or other adjustment). | The payment amounts under this section shall not be subject to any adjustment (including any geographic adjustment, budget neutrality adjustment, annual update, or other adjustment). | |||
| (b)(5) | (5) Sample collection fee | (5) Sample collection fee | ||
| In the case of a sample collected from an individual in a skilled nursing facility or by a laboratory on behalf of a home health agency, the nominal fee that would otherwise apply under section 1395l(h)(3)(A) of this title shall be increased by $2. | In the case of a sample collected from an individual in a skilled nursing facility or by a laboratory on behalf of a home health agency, the nominal fee that would otherwise apply under section 1395l(h)(3)(A) of this title shall be increased by $2. | |||
| (b)(6) | (6) [inserted: Default payment for widely available non-ADLT clinical diagnostic laboratory tests for periods for which there is no contract with an independent entity or with respect to which there is no data.—] | |||
| (b)(6)(A) | (A) [inserted: In general.—] | |||
| [inserted: With respect to data collection periods for reporting periods beginning on or after January 1, 2028, in the case of a widely available non-ADLT clinical diagnostic laboratory test with respect to which subsection (c) does not apply, if a circumstance described in subparagraph (B) applies with respect to such a reporting period and such a clinical diagnostic laboratory test, payment for such test under this section for a year beginning during the qualified rate period described in subparagraph (C), shall be equal to the amount of payment for such clinical diagnostic laboratory test under this section for the previous year, increased by the percentage increase in the Consumer Price Index for all urban consumers (all items; United States city average) over the previous year.] | ||||
| (b)(6)(B) | (B) [inserted: Circumstances described.—] | |||
| [inserted: For purposes of subparagraph (A), with respect to a data collection period and a widely available non-ADLT clinical diagnostic laboratory test, the circumstances described in this subparagraph are if the Secretary—] | ||||
| (b)(6)(B)(i) | (i) [inserted: ] | |||
| [inserted: is not able to enter into a contract under subsection (a)(1)(A)(ii) with a qualifying independent claims data entity with respect to such data collection period; or] | ||||
| (b)(6)(B)(ii) | (ii) [inserted: ] | |||
| [inserted: determines that there is no applicable information with respect to such clinical diagnostic laboratory test and data collection period in the qualifying comprehensive claims database of such qualifying independent claims data entity.] | ||||
| (b)(6)(C) | (C) [inserted: Qualified rate period described.—] | |||
| [inserted: For purposes of subparagraph (A), the qualified rate period, with respect to a data collection period and a widely available non-ADLT clinical diagnostic test to which a circumstance described in subparagraph (B) applies, is the period—] | ||||
| (b)(6)(C)(i) | (i) [inserted: ] | |||
| [inserted: beginning on the first day of the second year following the first data collection period with respect to which such circumstance applies with respect to such test; and] | ||||
| (b)(6)(C)(ii) | (ii) [inserted: ] | |||
| [inserted: ending with the last day of the year following the first data collection period with respect to which such circumstance no longer applies with respect to such test.] | ||||
| (b)(7) | (7) [inserted: Payment for non-widely available non-ADLT clinical diagnostic laboratory tests for which there is no applicable information.—] | |||
| (b)(7)(A) | (A) [inserted: In general.—] | |||
| [inserted: For determining payment under this subsection for a year in the case of a non-widely available non-ADLT clinical diagnostic laboratory test with respect to which subsection (c) does not apply, if the Secretary determines that no applicable information has been reported under subsection (a)(1)(A)(i) by any applicable laboratory for such test with respect to the most recent data collection period (beginning with data collection periods for reporting periods beginning on or after January 1, 2028), payment for such test under this section for such year shall be determined as follows:] | ||||
| (b)(7)(A)(i) | (i) [inserted: ] | |||
| [inserted: In the case that a process described in subparagraph (B) was not applied pursuant to this subparagraph for determining payment for such test for a previous year with respect to such data collection period, payment for such test and year shall be determined using such a process.] | ||||
| (b)(7)(A)(ii) | (ii) [inserted: ] | |||
| [inserted: In the case that a process described in subparagraph (B) was applied pursuant to this subparagraph for determining payment for such test for a previous year with respect to such data collection period, payment for such test and year shall be equal to the amount of payment for such test under this section for the previous year.] | ||||
| (b)(7)(B) | (B) [inserted: Process described.—] | |||
| [inserted: For purposes of subparagraph (A), a process described in this subparagraph, with respect to a non-widely available non-ADLT clinical diagnostic laboratory test for which there is no reported data (as described in such subparagraph) with respect to a data collection period, is—] | ||||
| (b)(7)(B)(i) | (i) [inserted: ] | |||
| [inserted: cross-walking (as described in section 414.508(a) of title 42, Code of Federal Regulations, or any successor regulation) to the most appropriate clinical diagnostic laboratory test under the fee schedule under this section during that period; or] | ||||
| (b)(7)(B)(ii) | (ii) [inserted: ] | |||
| [inserted: if no other clinical diagnostic laboratory test is comparable to the test for which there is no reported applicable information, according to the gapfilling process described in subsection (c)(2).] | ||||
| (b)(8) | (8) [inserted: Explanation of payment rates.—] | |||
| [inserted: In the case of a clinical diagnostic laboratory test for which payment is made under this subsection, the Secretary shall make available to the public an explanation of the payment rate for such test, including any supporting data as may be necessary for a laboratory to assess the accuracy of the calculations.] | ||||
| (c) | (c) Payment for new tests that are not advanced diagnostic laboratory tests | (c) Payment for new tests that are not advanced diagnostic laboratory tests | ||
| (c)(1) | (1) Payment during initial period | (1) Payment during initial period | ||
| In the case of a clinical diagnostic laboratory test that is assigned a new or substantially revised HCPCS code on or after April 1, 2014, and which is not an advanced diagnostic laboratory test (as defined in subsection (d)(5)), during an initial period until payment rates under subsection (b) are established for the test, payment for the test shall be determined— | In the case of a clinical diagnostic laboratory test that is assigned a new or substantially revised HCPCS code on or after April 1, 2014, and which is not an advanced diagnostic laboratory test (as defined in subsection (d)(5)), during an initial period until payment rates under subsection (b) are established for the test, payment for the test shall be determined— | |||
§ 1395m–1(c)–(d)
(c)(1)(A)–(2)(D) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (c)(2)(E) | (E) | (E) | ||
| Other criteria the Secretary determines appropriate. | Other criteria the Secretary determines appropriate. | |||
| (c)(3) | (3) Additional consideration | (3) Additional consideration | ||
| In determining the payment amount under crosswalking or gapfilling processes under this subsection, the Secretary shall consider recommendations from the panel established under subsection (f)(1). | In determining the payment amount under crosswalking or gapfilling processes under this subsection[inserted: or subsection (b)(7)], the Secretary shall consider recommendations from the panel established under subsection (f)(1). | |||
| (c)(4) | (4) Explanation of payment rates | (4) Explanation of payment rates | ||
| In the case of a clinical diagnostic laboratory test for which payment is made under this subsection, the Secretary shall make available to the public an explanation of the payment rate for the test, including an explanation of how the criteria described in paragraph (2) and paragraph (3) are applied. | In the case of a clinical diagnostic laboratory test for which payment is made under this subsection, the Secretary shall make available to the public an explanation of the payment rate for the test, including an explanation of how the criteria described in paragraph (2) and paragraph (3) are applied. | |||
| (d) | (d) Payment for new advanced diagnostic laboratory tests | (d) Payment for new advanced diagnostic laboratory tests |
§ 1395m–1(g)–(i)
(d)(1)–(g)(1) unchanged
| Where | Mark | The Code now | Mark | As the bill would leave it |
|---|---|---|---|---|
| (g)(2) | (2) Designation of one or more medicare administrative contractors for clinical diagnostic laboratory tests | (2) Designation of one or more medicare administrative contractors for clinical diagnostic laboratory tests | ||
| The Secretary may designate one or more (not to exceed 4) medicare administrative contractors to either establish coverage policies or establish coverage policies and process claims for payment for clinical diagnostic laboratory tests, as determined appropriate by the Secretary. | The Secretary may designate one or more (not to exceed 4) medicare administrative contractors to either establish coverage policies or establish coverage policies and process claims for payment for clinical diagnostic laboratory tests, as determined appropriate by the Secretary. | |||
| (h) | (h) Implementation | (h) Implementation | ||
| (h)(1) | (1) Implementation | (1) Implementation | ||
| There shall be no administrative or judicial review under section 1395ff of this title, section 1395oo of this title, or otherwise, of the establishment of payment amounts under this section. | There shall be no administrative or judicial review under section 1395ff of this title, section 1395oo of this title, or otherwise, of the establishment of payment amounts under this section[inserted: before January 1, 2029]. | |||
| (h)(2) | (2) Administration | (2) Administration | ||
| Chapter 35 of title 44 shall not apply to information collected under this section. | Chapter 35 of title 44 shall not apply to information collected under this section. | |||
| (h)(3) | (3) Funding | (3) Funding | ||
| For purposes of implementing this section, the Secretary shall provide for the transfer, from the Federal Supplementary Medical Insurance Trust Fund under section 1395t of this title, to the Centers for Medicare & Medicaid Services Program Management Account, for each of fiscal years 2014 through 2018, $4,000,000, and for each of fiscal years 2019 through 2023, $3,000,000. Amounts transferred under the preceding sentence shall remain available until expended. | For purposes of implementing this section, the Secretary shall provide for the transfer, from the Federal Supplementary Medical Insurance Trust Fund under section 1395t of this title, to the Centers for Medicare & Medicaid Services Program Management Account, for each of fiscal years 2014 through 2018, $4,000,000, and for each of fiscal years 2019 through 2023, $3,000,000. Amounts transferred under the preceding sentence shall remain available until expended. | |||
| (i) | (i) Transitional rule | (i) Transitional rule | ||
| During the period beginning on April 1, 2014, and ending on December 31, 2016, with respect to advanced diagnostic laboratory tests under this part, the Secretary shall use the methodologies for pricing, coding, and coverage in effect on the day before April 1, 2014, which may include cross-walking or gapfilling methods. | During the period beginning on April 1, 2014, and ending on December 31, 2016, with respect to advanced diagnostic laboratory tests under this part, the Secretary shall use the methodologies for pricing, coding, and coverage in effect on the day before April 1, 2014, which may include cross-walking or gapfilling methods. |